Acadia Pharmaceuticals (ACAD) Capital Expenditures Growth (1y) (2013 - 2025)
Acadia Pharmaceuticals (ACAD) Capital Expenditures Growth (1y) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 472.40 Bn | 467.61 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 122.23 Bn | 114.98 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - | - |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | 143.40% |
| 10 | Acadia Pharmaceuticals | 4.35 Bn | 3.50 Bn | 243.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 784.11% |
| Sep 30, 2025 | 454.29% |
| Dec 31, 2021 | -99.95% |
| Jun 30, 2021 | -98.47% |
| Mar 31, 2021 | 15.20% |
| Dec 31, 2020 | 865.70% |
| Sep 30, 2020 | 2,051.25% |
| Jun 30, 2020 | 14,565.00% |
| Mar 31, 2020 | 13.63% |
| Dec 31, 2019 | -60.65% |
| Sep 30, 2019 | -92.12% |
| Jun 30, 2019 | -82.61% |
| Mar 31, 2019 | 83.48% |
| Dec 31, 2018 | 7,414.29% |
| Sep 30, 2018 | 1,712.50% |
| Jun 30, 2018 | -56.44% |
| Mar 31, 2018 | -7.63% |
| Dec 31, 2017 | -97.19% |
| Sep 30, 2017 | -88.09% |
| Jun 30, 2017 | -54.48% |